Saratoga Aggressive Balanced Allc A holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Saratoga Aggressive Balanced Allocation Portfolio Class A SABAX
- NAV / 1-Day Return 12.71 / −0.31 %
- Total Assets 1.9M
-
Adj. Expense Ratio
2.530%
- Expense Ratio 1.240%
- Distribution Fee Level High
- Share Class Type Front Load
- Category Moderately Aggressive Allocation
- Investment Style Mid Blend
- Credit Quality / Interest Rate Sensitivity Medium/Moderate
- Status Open
- TTM Yield 1.96%
- Turnover 3%
USD | NAV as of Jul 22, 2026 | 1-Day Return as of Jul 22, 2026, 11:15 PM GMT+0
Morningstar’s Analysis SABAX
Will SABAX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 93.0
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Saratoga Large Capitalization Growth I | 16.00 | 297,220 | — |
Vanguard Interm-Term Bond Index Adm | 15.01 | 278,889 | — |
Saratoga Large Capitalization Value I | 13.67 | 254,065 | — |
Saratoga Mid Capitalization I | 13.27 | 246,542 | — |
Saratoga Small Capitalization I | 10.44 | 194,023 | — |
Vanguard Total Intl Stock Index Admiral | 8.48 | 157,570 | — |
BNY Dreyfus Instl Pref Govt MMkt Instl | 7.48 | 138,924 | Cash and Equivalents |
Saratoga Technology & Comm I | 7.05 | 130,925 | — |
Eaton Vance Glbl Macr Absolute Return I | 3.85 | 71,597 | — |
Saratoga Health & Biotechnology I | 3.37 | 62,612 | — |